Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritis

Overview of attention for article published in Arthritis Research & Therapy, December 2022

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (89th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

So far, Altmetric has seen 2 news stories from 2 outlets.

An analysis of 2 phase 3 studies of secukinumab (Cosentyx, Novartis) in patients with psoriatic arthritis (PsA) showed…

Patients with psoriatic arthritis (PsA) have a substantial prevalence of radiographic damage at baseline, which was associated…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.